Status:
UNKNOWN
Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity
Lead Sponsor:
Istanbul Medeniyet University
Conditions:
Type 2 Diabetes
Insulin Resistance
Eligibility:
All Genders
19-79 years
Phase:
NA
Brief Summary
This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship bet...
Detailed Description
Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive w...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Insulin resistance
- Obesity disease
Exclusion
- Pediatric individuals
- All patients who are hospitalized,
- Liver disease
- Cancer patients
- Disease related to the gastrointestinal tract
- Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
- Neurological disease
Key Trial Info
Start Date :
March 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04298515
Start Date
March 2 2020
End Date
March 31 2021
Last Update
March 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haydarpaşa Numune Education and Research Hospital
Istanbul, Turkey (Türkiye)